Theorem Clinical Research

Cellceutix

Cellceutix’s Kevetrin shows positive results

Wednesday, March 9, 2011 01:45 PM

Cellceutix has reported its cancer compound, Kevetrin, has demonstrated potent anti-tumor activity in the treatment of leukemia cells in a hematopoietic xenograft tumor model.  The activity is attributed to the reactivation of p53, the "Guardian Angel" protein, which Cellceutix announced as a major breakthrough in cancer research.

More... »

Quest Diagnostics


CWWeekly

March 23

Industry welcomes FDA draft guidance outlining the use of electronic Informed Consent for trials

Apple launches ResearchKit platform to tap millions of iPhone users to enroll in observational studies using apps

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs